BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35996877)

  • 21. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
    Watanabe A; Kotsuma M
    Drug Metab Pharmacokinet; 2024 Apr; 55():101000. PubMed ID: 38458122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
    Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.
    Dave N; Gopalakrishnan S; Mensing S; Salem AH
    Clin Transl Sci; 2019 Nov; 12(6):625-632. PubMed ID: 31268229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
    Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
    Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
    Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
    Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
    Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
    Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
    Ji T; Chen X; Yeleswaram S
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.